Kornimate/medical-research-clean huggingface dataset:
mivacurium chloramine muscle relaxation effect in patients with liver cirrhosis

Conditions: Liver Dysfunction

Summary: observed the muscle relaxation of mivacurium in patients with liver cirrhosis.clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon

the liver is an important organ of the body to maintain life activities, material and energy metabolism, and the main organ of biotransformation and elimination of toxic substances and drugs, have many complex functions. anesthetic drugs mostly through liver transformation and degradation.liver cirrhosis, liver cancer patients due to abnormal liver dysfunction and liver metabolism, most of the muscle relaxant prone to muscle relaxant accumulation and delayed recovery of patients with liver cirrhosis. mivacurium is a new type of non depolarizing muscle relaxants，has the characteristics of rapid onset, short duration of action. mivacurium can produce similar clinical effect of depolarizing muscle relaxant succinylcholine, and rapidly be blood che catabolism, without liver metabolism. it can either as a single vein for medicinal endotracheal intubation, or as maintain continuous intravenous auxiliary anesthesia drug , is a muscle relaxant to shorten the clinical anesthesia recovery period ideal.

Eligibility criteria:
inclusion criteria: * patients volunteered for the clinical research and signed a written informed consent * experimental group patients is cirrhosis of the liver (liver function grade child - pugh, grade a) ready to abdominal surgery patients; the control group was no cirrhosis, ready to abdominal surgery patients * aged 18 \~ 60 * bmi\<28kg/㎡ * the american society of anesthesiologists (asa) class i \~ ii exclusion criteria: * systolic blood pressure ≥180 mm hg or \< 90 mm hg, diastolic blood pressure ≥110 mm hg or \< 60 mm hg * serious heart, brain, liver, kidney, lung, endocrine diseases or serious infection * patients with difficult airway (such as mallampati airway class iii, airway abnormalities, etc.) * hr \< 50 times/min * the patient had a history of mental illness or chronic psychiatric drugs, chronic pain medication history * history of alcoholism * patients with neuromuscular system disease * has a tendency to malignant hyperthermia * the patient used to test drug allergies or other contraindications * over the past 30 days participated in other clinical drug research

Keywords: mivacurium chloramine patients with liver cirrhosis muscle relaxation effect
fludarabine, cyclophosphamide, and alemtuzumab in patients with b-cell chronic lymphatic leukemia (b-cll)

Conditions: B-cell Chronic Lymphocytic Leukemia

Summary: this study aims to assess the short term efficacy of a combination immunochemotherapy in patients with relapsed b-cell chronic lymphatic leukemia.


Eligibility criteria:
inclusion criteria: * b-cll in need of treatment * one or two prior prior therapies * who performance status 0-2 exclusion criteria: * serum creatinine \> 1.5 uln * major organ dysfunctions * pregnant or nursing

Keywords: cll immunochemotherapy
effectiveness of vibratory versus cold stimuli on pain perception in children

Conditions: Pain Perception

Summary: local anesthesia is an anxiety-provoking procedure. pain control is important for effective behavior guidance, specially among pediatric patients. this study aims to evaluate the effectiveness of buzzy® as a topical anesthetic in pain perception through two ways: once using vibration mode without the cold pack and the other using the cold pack without vibration and comparing it to topical anesthetic gel during different anesthetic techniques methods: a randomized controlled clinical trial involving 72 healthy cooperative patients aged 5-9 years. they will be allocated to receive local anesthesia either using the vibration mode of buzzy bee (test group) or the cold pack of buzzy bee (test group) or conventional topical anesthetic gel (control group). pain response will be assessed using visual analog scale (vas) and sem scale.


Eligibility criteria:
inclusion criteria: 1. patients indicated for simple restorative procedures. 2. children with physical status asa i, ii. 3. children with no learning disabilities 4. positive or definitely positive behavior during preoperative assessments according to the frankl scale. 5. patients whom parents will give consent to participate exclusion criteria: 1. patients allergic to local anesthesia or having a family history of allergy to local anesthesia. 2. patients with acute oral or facial infection (swelling and/or cellulites) 3. having active sites of pathosis in the area of injection that could affect anesthetic assessment. 4. children with special health care needs.
pain response evaluation of a combined intervention to cope effectively

Conditions: Chronic Pain

Summary: the purpose of this research is is to determine if the combination of non-opioid medication (duloxetine) and web-based pain-coping skills training (pcst) is beneficial for individuals with chronic musculoskeletal pain (cmp).

with this study, the study team hopes to address two important unanswered questions: (1) does combination treatment consisting of duloxetine and web-based cognitive behavioral therapy (cbt) optimize treatment outcomes? (2) would adherence-focused guidance delivered by nurse clinician using motivational interviewing (mi) techniques enhance treatment effectiveness? this study is significant because the study team aims to optimize pain-related treatment outcomes at the primary care level where most patients with pain are managed. importantly, the use of nurse clinician providing adherence-focused guidance (as opposed to content-focused guidance) on the continued practice (or use) of pain coping skills increases the likelihood that the study's intervention is scalable in the future. effective, accessible and scalable psychoeducational treatments are needed to manage cmp in real world clinic settings.

Eligibility criteria:
inclusion criteria: * patients at the primary care clinic with daily pain for 3 months or longer affecting the low back, neck, hip, knee or widespread pain; * at least moderate in bpi global pain severity exclusion criteria: * uncontrolled hypertension (because duloxetine rarely increases blood pressure) * active suicidal ideation * planned elective surgery during the study period (to avoid the confounding effect of possible complicated post-surgery recovery course on the primary outcome) * ongoing unresolved disability claims * inflammatory arthritis (e.g., lupus and ankylosing spondylitis) * cancer-related musculoskeletal pain * pregnancy * history of bipolar disorder or schizophrenia * narrow angle glaucoma * severe renal impairment (creatinine clearance \<30) * current use of duloxetine * current use of any of the following medications (to avoid adverse drug-to-drug interactions): tricyclic antidepressant \> 25 mg daily dose, monoamine oxidase inhibitors, fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, milnacipran, mirtazapine, gabapentin or aripiprazole, serotonin precursors (e.g., tryptophan), and strong cyp1a2 inhibitors (e.g., ciprofloxacin, other fluoroquinolones, fluvoxamine and verapamil)

Keywords: non-opioid pain medication psychoeducational treatments chronic musculoskeletal pain
treat-to-target prednisolon taper in patients with polymyalgia rheumatica

Conditions: Polymyalgia Rheumatica

Summary: polymyalgia rheumatica (pmr) has an incidence of approximately 1000/10\^6 for persons more than 50 years. treatment with prednisolone carries several significant adverse effects, and it is therefore essential to taper prednisolone as fast as possible. systematic treatment strategies (treat-to-target) is the most important improvement of disease management for other rheumatic diseases such as rheumatoid arthritis in the last decades. thus, the purpose is to investigate benefits and harms associated with a nurce led systematic prednisolone taper strategy at the department of rheumatology compared to individual treatment by discretion of the general practitioner. it is a 1-year open label randomised trial with a 1-year extension in 120 treatment naïve patients with pmr.


Eligibility criteria:
inclusion criteria: * patients newly diagnosed with pmr according to the eular criteria for pmr. * no sign of gca on ultrasonography of the temporal and axillary arteries. * age over 50 years. * danish spoken and written language skills sufficient to fill out questionnaires. exclusion criteria: * peroral, intraarticular or intramuscular application of glucocorticoids within the last month. * previous prednisolone treatment for gca/pmr. * unable to give consent. * symptoms of gca (newly onset-headache, tenderness of the temporal artery, jaw claudication, vision disturbances). * active malignant cancers within the last 5 years (except basal cell carcinoma). * other inflammatory rheumatic diseases (eg. rheumatoid arthritis, polymyositis, spondyloarthritis, psoriatic arthritits, gout). * uncontrolled diseases (eg severe active asthma, cardiac disease with nyha class iv)
a single-center evaluation of the anti-inflammatory effects of lastacaft as measured by in-vivo confocal microscopy

Conditions: Allergic Conjunctivitis

Summary: a single-center evaluation of the anti-inflammatory effects of lastacaft ® as measured by in-vivo confocal microscopy


Eligibility criteria:
inclusion criteria: * have a positive history of ocular allergies and a positive skin test to protocol defined allergens * have a positive cac reaction at visit 1 * have a positive conjunctival inflammation score at visit 1 exclusion criteria: * may not use disallowed medications in specified washout period * may not have an ocular or system disease the investigator feels with impact subject safety or trial parameters * may not have active ocular infection
heparin versus taurolidine to bloodstream infection prevention related in central venous catheter in children

Conditions: Catheter-Related Infections

Summary: clinical trial, that aim is evaluation of the use of taurolidine and heparin in the prevention of bloodstream infection in venous catheter in children with intestinal failure.

will be collected data about sociodemographics : date of birth, hospitalization and which is use (taurolidine or heparin), sex, underlying disease and associated co-morbidities. about central venous catheter will be collect: catheter type in each period, the number of lumens, date of insertion of each catheter usage time, reason for removal of the catheter insertion site and catheter material (silicone or polyurethane ). data relating to parenteral nutrition will also be collected: osmolarity of parenteral nutrition, infusion time every 24 hours and concentration of glucose parenteral nutrition bag. it will be used for aseptic handling technique of the solutions, as well as for handling the connections of the central catheter. for preparation and administration of taurolidine and heparin is used an operations manual that was made for the authors. patients are divided into two groups: taurolidine or heparin.

Eligibility criteria:
inclusion criteria: * the population will consist of patients 30 days of life to fourteen years old, admitted to the pediatric inpatient units, with intestinal failure receiving parenteral nutrition through a central venous catheter and at least eight weeks of use forecast. exclusion criteria: * children will be excluded other associated diseases that occur with frequent use of antibiotics, for example, cystic fibrosis, primary or acquired immunodeficiency. also excluded are the children admitted that they are not accompanied by a responsible family recognition, or accompanied by responsible under the age of 18 years. children with allergic reactions to the use of some of the solutions (taurolidine or heparin) will be suspended medication and receive appropriate treatment. although these children have stopped the use of medication, will be followed according to the assessment protocol by the end of the study.
empowering patients to better manage diabetes through self-care

Conditions: Type I or Type II Diabetes (Excludes Gestational Diabetes)

Summary: this study will look at the impact of health insurance benefits on self management of diabetes for people with this condition. studies have shown that when people with diabetes manage their disease better, they stay healthier. our goal in this study is to help those with diabetes better manage their disease (self-care). we will compare two types of health insurance benefits in this study. we want to see if one set of benefits improves self-care more than the other one.

the objective of this particular study is to determine if the addition of regular pharmacist visits to usual care can improve clinical outcomes in patients with diabetes. the central hypothesis is that a program overseen by community pharmacists that empowers patients to self-manage their diabetes will lead to improved clinical and humanistic outcomes and will be cost-effective. strong preliminary data collected from other sites suggests that patient empowerment programs are effective at reducing hemoglobin a1c after 12 months and in reducing the total cost of care. this hypothesis will be tested by pursuing three specific aims to evaluate the impact of a pharmacist-administered diabetes patient empowerment program on: 1. clinical markers for diabetes and related metabolic disorders; 2. the cost of care and resource utilization; and 3. patient knowledge and perceived ability to manage diabetes. there is an additional specific aim to assess the pharmacists with respect to satisfaction with the training program and the overall project, the activities conducted in patient sessions, and the time taken to complete the visits in this study.

Eligibility criteria:
inclusion criteria: * diabetes (type i or type ii) * enrolled in health plan with participating employer * age 18 or older * willing and able to provide informed consent exclusion criteria: * gestational diabetes

Keywords: diabetes
efficacy and safety of neosil on chronic effluvium

Conditions: Chronic Telogen Effluvium

Summary: the purpose of this study is to evaluate the efficacy of neosil in the treatment of chronic effluvium


Eligibility criteria:
inclusion criteria: * participants who present hair loss for more than 6 months; * do not use other possible cosmetic or dermatological treatments, during the trial; * not change the diet during the trial and not be any restrictive diet during this period. exclusion criteria: * pregnancy or risk of pregnancy and lactating patients; * use of any products to promote hair growth within the 6 months prior to the baseline visit; * history of hair transplants; * current skin disease; * history hypersensitivity to the active ingredients used in the study; * participation in clinical trial in the year prior to this study; * known history of non controled systemic disease (diabetes, hypertension, anemia, iron deficiency, and others); * gastric diseases; * smoker; * history of systemic disease (hiv, non specify autoimmune disease, hepatitis, and others).
evaluation of the efficacy of optometric rehabilitation on visual cognitive deficits in children

Conditions: Visual Cognitive Deficits

Summary: visual cognitive deficits in children are frequent, with an impact on working and daily activities. optometric therapy may improve those functions, however few studies have been performed. we aim to evaluate the efficacy of such therapy by a comparative study between two groups of children aged between 5 and 12 after 6 months of rehabilitation.


Eligibility criteria:
inclusion criteria: * visual cognitive deficits * normal intelligence exclusion criteria: * cerebral palsy * mental deficiency * visual acuity deficit

Keywords: visual cognitive deficits
analyzing how genetics may affect response to high blood pressure medications

Conditions: Hypertension; Coronary Disease; Cerebrovascular Accident

Summary: high blood pressure is one of the most common health problems in the united states. there are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications. it is believed that genetic variations may contribute to the inconsistent treatment response. this study will use genetic analysis to determine whether particular genes interact with high blood pressure medications to modify the risk of certain cardiovascular diseases.

high blood pressure affects nearly one in three individuals in the unites states. there are many factors that can cause high blood pressure, including family history and genetic traits, kidney disease, stress, diabetes, and diet. if left untreated, high blood pressure can increase one's risk for coronary heart disease (chd), stroke, heart attack, and heart failure. while high blood pressure can be managed with medication, people receiving medication treatment for high blood pressure are still variably at risk for chd and other cardiovascular conditions. this risk variation may stem from varying drug reactions that are likely due to genetics. this study will use genetic analysis to determine whether particular genes interact with high blood pressure medications to modify the risk of certain cardiovascular diseases. this is a continuation study to the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat), which included a randomized trial of the four high blood pressure drugs chlorthalidone, amlodipine, lisinopril, and doxazosin. using samples from allhat participants, this study will analyze the interactions of candidate gene pathways of relevance with medications from the allhat study. researchers will examine both single dna building blocks and multiple genes in the candidate gene pathways and determine whether their interaction with the allhat drugs modifies the risk of cardiovascular outcomes. researchers will perform genetic analysis on 96 genetic markers using structured association testing (sat) and false discovery rate (fdr) methods. these methods will control for population stratification and multiple testing. finally, the study will establish a mechanism for other researchers to continue further analysis of the genetic variants examined in this study.

Eligibility criteria:
inclusion criteria: * participant in the allhat study

Keywords: chd combined chd stroke combined cardiovascular disease (cvd) pharmacogenetics end-stage renal disease heart failure hospitalized/fatal heart failure angina coronary revascularizations chd mortality lisinopril chlorthalidone amlodipine doxazosin
virtual prostate biopsy protocol for patients on active surveillance and at risk of prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to examine the use of mri surveillance for patients with no prostate cancer, potential prostate cancer, or diagnosed low-grade prostate cancer.

this study will use mri instead of prostate biopsy in combination with regularly scheduled urologist visits, interval psa checks, and annual dre to help establish a non-invasive method for 1) participants with a negative prostate mri (pi-rads 1 or 2) who have never had a biopsy; 2) participants with a positive mri (pi-rads score of 3, 4, or 5) and negative mri-targeted biopsy pathology; and 3) monitoring participants with clinically diagnosed low risk prostate cancer who are on active surveillance. however, if at any point, clinical suspicion indicated either by the presence of suspicious lesions on the mri, rising psa, and/or positive dre arises, then an immediate biopsy will be performed.

Eligibility criteria:
inclusion criteria: * biopsy-naive patients with a negative prostate mri (pi-rads score 1 or 2); or * patients with a pi-rads score of 3, 4, or 5 on mri and a negative mr-targeted biopsy; or * patients on active surveillance with a negative prostate mri (pi-rads 1 or 2). exclusion criteria: * positive dre; * psa \> 10 ng/ml or unstable psa (doubling time \<3 years) during the last year prior to enrolling in this study; * psad \> 0.15 (calculated using most recent psa divided by mri prostate volume); * first degree relative diagnosed with prostate cancer * first degree relative diagnosed with a brca2 or lynch syndrome associated gene causing any cancer. * patient carries a mutation on brca2 or a mismatch repair gene associated with lynch syndrome (mlhl, msh2, msh6, pms2); known brca2 or known mismatch repair gene mutation in the family (lynch syndrome) and patient has not had testing; or family history consistent with brca2 or lynch syndrome and there is no known brca2 or mismatch repair gene in the family.

Keywords: magnetic resonance imaging (mri)
role and effectiveness of rapid diagnostic tests in home-based management of malaria

Conditions: Fever; Malaria

Summary: most malaria deaths occur within 48 hours of onset of symptoms, and in rural areas with poor access to health facilities, home management of malaria (hmm) can improve the timeliness of treatment and reduce malaria mortality by up to 50%. in order to maximize both coverage and impact, acts should be deployed in hmm programmes, as well as in formal health facilities. up to 80% of malaria cases are treated outside the formal health sector and shops are frequently visited as the first (and in some cases only) source of treatment. strategies to deploy acts in africa thus also need to examine the role of shops in home management and to ensure that drugs sold are appropriate. the current practice of presumptive treatment of any febrile illness as malaria (both at health facilities and in the context of hmm) based solely on clinical symptoms without routine laboratory confirmation, results in significant over-use of antimalarial drugs. with act being a more costly regimen, it is important to be more restrictive in its administration and rapid diagnostic tests (rdts) provide a simple means of confirming malaria diagnosis in remote locations lacking electricity and qualified health staff. this study therefore proposes to evaluate the feasibility, acceptability, and cost-effectiveness of using rdts to improve malaria diagnosis and treatment by community-based drug distributors.the accuracy of rdts, and the acceptability of this approach, will be evaluated in both low and high transmission areas.


Eligibility criteria:
inclusion criteria: * children aged between 6 months and 5 years (\< 5 years)reported with fever by the mother/ caretaker of the child * children with uncomplicated malaria/ fever episodes * children whose mothers consent to participate exclusion criteria: * children aged less 6 months or greater than 4 years (≥ 5 years) * children requiring referral to a health facility (severe malaria, complicated fever episode, convulsions/fits, loss of consciousness, and other danger signs) * children whose mothers refuse to consent

Keywords: history of fever measured fever